At Ichnos Sciences, we’re working to make real progress in science and medicine. Explore our recent publications to discover how we’re shifting medicine forward.
|04/17/2023||ISB 2001||Overcoming Mechanisms of Escape from Treatments for Multiple Myeloma by ISB 2001, a first-in-Class Trispecific BCMA and CD38 targeted T Cell Engager||Perro M. et al.||American Association for Cancer Research Annual Meeting|
|12/10/2022||ISB 2001||ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma by Targeting Two Antigens||Perro M. et al.||Presentation at the American Society of Hematology Annual Meeting|
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.